Dextran (DB09255): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Dextran is a complex, variable molecular weight polysaccharide of microbial origin, characterized by a dual pharmacological profile as both a plasma volume expander and an antithrombotic agent. Its primary structure, consisting of an α-1,6 linked D-glucose backbone with periodic branches, dictates its physicochemical properties and, consequently, its therapeutic applications and risks. The clinical utility of Dextran is fundamentally governed by its molecular weight, with two principal fractions, Dextran 40 and Dextran 70, exhibiting distinct pharmacokinetic and pharmacodynamic profiles.

As a plasma volume expander, Dextran exerts a colloid osmotic pressure within the intravascular space, drawing fluid from the interstitium to restore circulating volume. This hemodynamic effect is central to its indication for the adjunctive treatment of hypovolemic shock arising from hemorrhage, surgery, or trauma. Concurrently, Dextran modulates hemostasis by reducing erythrocyte aggregation, decreasing platelet adhesiveness, lowering levels of key coagulation factors, and promoting fibrinolysis. These antithrombotic properties underpin its use in the prophylaxis of venous thromboembolism during high-risk surgical procedures.

Beyond these primary roles, Dextran serves as a critical carrier molecule in the Iron Dextran complex, a parenteral formulation for treating iron-deficiency anemia in patients who cannot tolerate or respond to oral iron. In this capacity, the Dextran shell stabilizes the ferric hydroxide core, enabling a controlled release of iron and mitigating toxicity. Dextran is also a ubiquitous component in ophthalmic lubricating solutions and has emerged as a versatile platform technology in biomedical research and advanced drug delivery systems, including nanoparticles, hydrogels, and chromatography matrices.

The clinical use of Dextran is tempered by a significant safety profile, dominated by the risk of severe, and potentially fatal, anaphylactoid reactions. Other major concerns include fluid overload, acute renal failure, and dose-dependent coagulopathy. This complex risk profile has necessitated stringent administration protocols and has contributed to a shift in its clinical standing, from a frontline therapeutic to a more specialized agent. Its inclusion on the World Health Organization's Model List of Essential Medicines highlights its enduring value in specific healthcare contexts, while market trends in developed nations suggest a concurrent evolution towards its application as a sophisticated excipient and platform for future medical technologies.

Section 1: Chemical and Physical Characterization of Dextran

1.1. Molecular Structure and Composition

Dextran is a complex, branched glucan, a high-molecular-weight polysaccharide composed of repeating D-glucose monomer units.[1] It is a naturally derived biopolymer, synthesized from sucrose-containing media by various strains of lactic acid bacteria, most notably

Leuconoc mesenteroides B512F and Streptococcus mutans.[3] The International Union of Pure and Applied Chemistry (IUPAC) defines dextrans as "Branched poly-

α-d-glucosides of microbial origin having glycosidic bonds predominantly C-1 → C-6".[7]

The fundamental structure of Dextran consists of a linear backbone of D-glucopyranosyl units joined by α-1,6 glycosidic linkages.[3] This primary chain accounts for approximately 95% of the linkages in the polymer.[9] The polymer's branched nature arises from side chains that are attached to the main backbone, most commonly via

α-1,3 glycosidic bonds.[3] Other linkage types, including

α-1,2 and α-1,4, may also be present, with the specific structure and degree of branching dependent on the microbial strain used for production.[5] In native, unfractionated Dextran, the degree of branching is approximately 5% and tends to decrease as the overall molecular weight of the polymer is reduced through hydrolysis and fractionation.[3] The branches are typically short, consisting of only one or two glucose units in length.[3]

The general chemical formula for Dextran is represented as (C6​H10​O5​)n​ or H(C6​H10​O5​)x​OH.[1] The molecular weight of native Dextran can be extremely high, ranging from 9 million to 500 million Daltons (Da).[9] For pharmaceutical use, this native polymer is hydrolyzed and fractionated to produce preparations with specific, controlled molecular weight distributions.[9] The complex structure is reflected in its formal IUPAC name: 2,3,4,5-tetrahydroxy-6-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}hexanal.[16]

1.2. Physicochemical Properties and Stability

Dextran is a white to off-white, tasteless, hygroscopic solid or crystalline powder.[5] Its physical properties are highly dependent on its molecular weight, but several key characteristics are consistent across clinically used fractions.

Solubility and Solution Properties: Dextran is highly soluble in water and various aqueous electrolyte solutions, readily forming clear, stable solutions.[3] Concentrated solutions exceeding 50% w/v can be prepared.[3] As a neutral polysaccharide, its solubility and solution viscosity are not significantly affected by changes in pH or salt concentration.[18] The solutions exhibit Newtonian flow characteristics, meaning their flow rate is independent of shear stress.[12] Dextran is also soluble in certain polar organic solvents, including dimethyl sulfoxide (DMSO), formamide, ethylene glycol, and glycerol, but it is insoluble in monohydric alcohols like methanol and ethanol, as well as most ketones.[3]

Stability: In its dry, powdered form, Dextran is very stable and can be stored for more than five years in airtight containers at room temperature.[3] It is hygroscopic and will absorb moisture if not properly sealed.[3] Aqueous Dextran solutions are stable and can be sterilized by autoclaving at temperatures of 110–115 °C for 30 to 45 minutes.[3] Solution stability is optimal at a pH between 6 and 7 but is maintained across a range of pH 4 to 10.[3] Dextran is incompatible with strong oxidizing agents and can be hydrolyzed by strong acids at high temperatures.[9]

Biocompatibility and Biodegradability: Dextran has a long history of use in human medical products and is considered biocompatible and biodegradable.[3] It is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration (FDA).[3] In the body, it is eventually broken down by the enzyme dextranase into glucose, which is metabolized to carbon dioxide and water.[3]

1.3. Analysis of Clinically Relevant Molecular Weight Fractions (Dextran 40 and Dextran 70)

The therapeutic utility and physiological behavior of Dextran are almost entirely dictated by its molecular weight. This parameter is not merely a classification but the master variable that controls the drug's osmotic pressure, viscosity, mechanism of action, and pharmacokinetic profile, particularly its route and rate of elimination. Consequently, different molecular weight fractions are employed for distinct clinical purposes. The two most prominent fractions in clinical use are Dextran 40 and Dextran 70, named for their weight-average molecular weight (Mw​) in kilodaltons (kDa).[3]

Dextran 40, also known as Low Molecular Weight Dextran (LMD), has an average molecular weight of approximately 40,000 Da.[4] Due to its smaller size, a 10% solution of Dextran 40 exerts a higher colloid osmotic pressure than an equivalent concentration of plasma proteins, making it a potent agent for rapid plasma volume expansion.[9] Its smaller size also facilitates more rapid renal excretion compared to larger fractions. These properties, combined with its significant effects on blood rheology, have made Dextran 40 the most popular fraction for antithrombotic therapy.[7]

Dextran 70, classified as a high molecular weight dextran, has an average molecular weight of approximately 70,000 Da.[10] A 6% solution of Dextran 70 exerts a colloid osmotic pressure that is similar to that of endogenous plasma proteins, providing a more isotonic and sustained volume expansion.[9] Because its molecular weight largely exceeds the threshold for glomerular filtration, it is cleared from the circulation much more slowly than Dextran 40, relying primarily on enzymatic metabolism. This results in a prolonged plasma-expanding effect.

The conformation of the Dextran polymer in solution also varies with its size. Molecules with a molecular weight below 2,000 Da are more rod-like, while those in the 2,000 to 10,000 Da range behave as expandable coils. At molecular weights above 10,000 Da, as seen with Dextran 40 and 70, the molecules behave as if they are highly branched and attain greater symmetry.[9] This structural behavior influences their interaction with blood components and their overall rheological effects. The critical differences between these two key formulations are summarized in Table 1.

Table 1: Comparative Physicochemical and Clinical Properties of Dextran 40 and Dextran 70

Property	Dextran 40 (LMD)	Dextran 70	Clinical Implication
Average Molecular Weight (Mw​)	~40,000 Da 5	~70,000 Da 10	Determines osmotic pressure, viscosity, and elimination pathway.
Typical Solution Concentration	10% in D5W or 0.9% NaCl 21	6% in 0.9% NaCl 9	Concentrations are calibrated to achieve desired osmotic effects.
Colloid Osmotic Pressure	Hyper-oncotic (higher than plasma) 9	Iso-oncotic (similar to plasma) 9	Dextran 40 provides rapid, potent fluid shift; Dextran 70 provides sustained, isotonic volume replacement.
Primary Clinical Emphasis	Antithrombosis; rapid volume expansion 7	Sustained volume expansion 8	Dextran 40 is preferred for improving microcirculation and preventing clots; Dextran 70 is preferred for treating hypovolemia.
Renal Excretion Rate	High (~70% excreted in 24 hrs) 7	Low (poorly excreted by kidneys) 7	Dextran 40 is cleared relatively quickly; Dextran 70 persists in circulation, increasing risk of accumulation.
Plasma Half-Life	Shorter (~10 hours) 8	Longer (~42-80 hours) 8	Dextran 70 provides a more prolonged therapeutic effect but also a longer duration of potential adverse effects.

Section 2: Comprehensive Pharmacological Profile

2.1. Mechanisms of Action

Dextran exerts its therapeutic effects through two distinct but synergistic mechanisms: a primary hemodynamic action as a plasma volume expander and a secondary hemostatic action as an antithrombotic agent. The interplay between these mechanisms underpins its utility in treating shock and preventing thromboembolic events.

2.1.1. Hemodynamic Effects: Plasma Volume Expansion and Microcirculatory Enhancement

The fundamental action of Dextran is the enhancement of blood flow, particularly within the microcirculation.[20] This is achieved through its function as a plasma volume expander.[26] As a large polysaccharide colloid, Dextran is largely confined to the intravascular space following intravenous administration. Here, it exerts a significant colloid osmotic pressure, creating an osmotic gradient that draws fluid from the interstitial and extravascular compartments into the circulation.[5] This fluid shift rapidly increases the total circulating blood volume.[20]

The increase in intravascular volume leads to a cascade of beneficial hemodynamic effects. It produces significant increases in central venous pressure, cardiac output, stroke volume, and systemic blood pressure, while concurrently reducing peripheral vascular resistance.[20] The expansion of plasma volume also results in hemodilution, a decrease in the concentration of red blood cells and plasma proteins.[4] This hemodilution reduces whole blood viscosity, further improving the rheological properties of blood and facilitating its flow through narrow capillaries.[20] The combination of increased volume and decreased viscosity enhances peripheral blood flow, releases sequestered blood cells, and increases venous return to the heart.[20] These actions are critical for restoring tissue perfusion in states of hypovolemic shock.[29]

2.1.2. Hemostatic Effects: Antithrombotic and Fibrinolytic Properties

In addition to its hemodynamic effects, Dextran possesses multifaceted antithrombotic properties that are crucial for its use in VTE prophylaxis.[7] These effects are not achieved by blocking the fibrinogen-fibrin conversion pathway like traditional anticoagulants, but rather by modulating other key components of thrombus formation and resolution.[20]

First, Dextran alters the surface properties of blood components. It binds to the surfaces of erythrocytes, platelets, and the vascular endothelium, increasing their electronegativity.[7] This increased negative charge reduces red blood cell aggregation (rouleaux formation) and decreases platelet adhesiveness, thereby inhibiting two initial steps in thrombus formation.[7]

Second, Dextran interacts with specific coagulation factors. It has been shown to reduce levels of Factor VIII-associated antigen von Willebrand factor (vWF), a key protein that mediates platelet adhesion to injured vessel walls, thus further impairing platelet function.[7] Doses of Dextran 40 approximating 15 mL/kg can also depress levels of factors V and IX to a degree greater than that expected from hemodilution alone.[29]

Third, Dextran promotes fibrinolysis, the enzymatic breakdown of clots. Preclinical studies suggest a mechanism involving the blockage of tissue plasminogen activator (tPA) uptake by mannose-binding receptors in the liver, which enhances endogenous fibrinolysis by increasing circulating tPA levels.[4] Furthermore, Dextran inhibits

α-2 antiplasmin, a primary inhibitor of plasmin, effectively acting as a plasminogen activator and possessing inherent thrombolytic features.[7]

Finally, clots that do form in the presence of Dextran have an altered structure. They are characterized by more evenly distributed platelets and a coarser fibrin meshwork, which renders them more susceptible to enzymatic degradation by plasmin.[7] The magnitude of these hemostatic effects—prolonging bleeding time, reducing emboli, and decreasing platelet adhesiveness—is directly proportional to the molecular weight of the Dextran fraction administered.[4]

The hemodynamic and hemostatic effects of Dextran are not independent but are functionally linked. The volume expansion and subsequent hemodilution improve microcirculatory flow and reduce vascular stasis, one of the three pillars of Virchow's triad for thrombosis. This physical disruption of stasis provides a powerful synergistic effect, complementing the direct biochemical inhibition of platelet aggregation and promotion of fibrinolysis to produce a robust overall antithrombotic outcome.[20]

2.2. Pharmacokinetics: An ADME Analysis

The absorption, distribution, metabolism, and excretion (ADME) of Dextran are fundamentally governed by its molecular weight. This relationship creates a therapeutic trade-off, where formulations with prolonged efficacy also carry an increased risk of accumulation and associated toxicities.

2.2.1. Absorption and Bioavailability

Dextran exhibits very low oral bioavailability, which decreases as the length of the polysaccharide chain increases.[4] Due to this poor absorption from the gastrointestinal tract, Dextran must be administered intravenously for systemic therapeutic effects such as plasma volume expansion or antithrombosis.[32]

2.2.2. Distribution

Following intravenous infusion, Dextran is rapidly and evenly distributed throughout the circulating blood volume.[4] Its large molecular size prevents it from readily crossing intact capillary walls, thus retaining it within the intravascular space where it exerts its osmotic effects.[7] This retention is further enhanced by its ability to bind to plasma proteins, including albumin.[4] Over time, some molecules diffuse into the extravascular compartment and are temporarily taken up by the macrophages of the reticuloendothelial system (RES), particularly in the liver and spleen, which are the primary sites of tissue accumulation.[3] Some of these molecules are eventually returned to the intravascular compartment via the lymphatic system.[20]

2.2.3. Metabolism and Biodegradation

Dextran is slowly metabolized in the body by the enzyme dextranase, which is found primarily in the liver, spleen, and other tissues of the RES.[3] Dextranase hydrolyzes the polymer's glycosidic bonds, breaking it down into smaller glucose units.[3] This glucose then enters normal metabolic pathways and is ultimately oxidized to carbon dioxide and water.[20] The rate of metabolism is slow, and it is the primary elimination pathway for high-molecular-weight fractions (e.g., Dextran 70) that cannot be efficiently cleared by the kidneys.[4]

2.2.4. Excretion and Elimination Half-Life

The elimination of Dextran from the body is highly dependent on its molecular weight, as this determines its ability to pass through the glomerular filtration barrier in the kidneys.[4]

There is a molecular weight threshold for unrestricted glomerular filtration, reported to be between 15 kDa and 50 kDa.[4]

• Low Molecular Weight Fractions (e.g., Dextran 40): A significant portion of Dextran 40 molecules falls below this renal threshold. Consequently, they are readily filtered by the kidneys and excreted unchanged in the urine. Approximately 70% of an administered dose of Dextran 40 is eliminated via this renal route within the first 24 hours.[7] The remaining 30% is retained longer and cleared through metabolic pathways.[7]
• High Molecular Weight Fractions (e.g., Dextran 70): Dextran 70 and other fractions with molecular weights greater than 60 kDa are poorly excreted by the kidneys.[7] These larger molecules remain in the blood for extended periods, for as long as weeks, until they are slowly metabolized by the RES.[7]

This size-dependent clearance directly impacts the elimination half-life. The half-life of Dextran is directly proportional to its molecular weight, ranging from approximately 1.9-2 hours for very small fractions (Dextran 1) to around 10 hours for Dextran 40, and extending significantly to 42-80 hours for Dextran 60 and Dextran 70.[4] This pharmacokinetic profile presents a clinical challenge: the longer half-life of Dextran 70 provides more sustained volume expansion, but this same property increases the risk of fluid overload, renal accumulation, and prolonged interference with hemostasis. Conversely, the shorter half-life of Dextran 40 mitigates these risks but may require more frequent administration to maintain its therapeutic effect.

Section 3: Clinical Efficacy and Therapeutic Applications

Dextran's unique physicochemical and pharmacological properties have led to its application across a diverse range of clinical settings. Its primary roles are centered on fluid resuscitation and thrombosis prevention, but its utility extends to ophthalmology and, most critically, as an indispensable carrier for parenteral iron therapy.

3.1. Management of Hypovolemia and Shock

Dextran is indicated as an adjunctive therapy for the treatment of shock or impending shock due to conditions such as hemorrhage, burns, surgery, or other trauma.[4] It functions as a plasma volume expander, rapidly restoring the circulating blood volume by osmotically drawing fluid into the vasculature.[5] This makes it a valuable tool for early fluid replacement, particularly in emergency situations when whole blood or other blood products are not immediately available.[5] It is important to note that Dextran is not a substitute for blood or its components, as it does not possess oxygen-carrying capacity or provide coagulation factors.[21] Both Dextran 40 and Dextran 70 are used for this purpose. Dextran 70, in particular, is recognized for its efficacy in treating hypovolemia and is included on the World Health Organization's Model List of Essential Medicines for this indication.[8]

3.2. Prophylaxis of Venous Thromboembolism (VTE)

Leveraging its antithrombotic properties, Dextran—primarily the Dextran 40 fraction—is indicated for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE).[4] This use is particularly relevant for patients undergoing surgical procedures known to be associated with a high risk of thromboembolic complications, such as hip surgery.[21] By reducing platelet adhesiveness, improving microcirculatory flow, and altering fibrin structure to enhance lysability, Dextran helps to prevent the formation of dangerous postoperative clots.[7]

3.3. Ophthalmic Formulations for Ocular Lubrication

Dextran is a common active ingredient in numerous over-the-counter ophthalmic preparations, or "artificial tears".[4] These products are used for the temporary relief of symptoms associated with dry eyes (xerophthalmia), such as burning, itching, and minor irritation caused by environmental factors like wind and sun.[5] In these formulations, Dextran 70 is often used for its lubricating properties.[37] It increases the viscosity and residence time of the solution on the surface of the eye, helping to keep the cornea moist, protect it from injury, and alleviate discomfort.[24] In this context, Dextran's function is purely physical, blurring the line between an active pharmaceutical ingredient and a critical excipient.

3.4. The Role of Dextran in Iron-Deficiency Anemia: The Iron Dextran Complex

One of the most significant and enduring clinical applications of Dextran is as a carrier molecule in parenteral iron therapy. Iron Dextran is a complex formulation consisting of a ferric hydroxide core surrounded by a dextran carbohydrate shell.[42] This product is an FDA-approved treatment for patients with documented iron-deficiency anemia for whom oral iron therapy is contraindicated, not tolerated, or has proven ineffective.[43] This is a critical therapy for patient populations with chronic conditions leading to iron malabsorption (e.g., inflammatory bowel disease, celiac disease, gastric bypass) or significant ongoing blood loss, as well as for many patients with chronic kidney disease.[43]

The role of the dextran component is paramount. Free iron is highly reactive and toxic. The dextran shell stabilizes the iron core, preventing the uncontrolled release of iron into the bloodstream.[42] After intravenous or intramuscular administration, the Iron Dextran complex is taken up by macrophages of the reticuloendothelial system. Within these cells, the complex is broken down, and the iron is slowly and safely released to be bound by transferrin for transport to the bone marrow for erythropoiesis or stored as ferritin.[42] This controlled-release mechanism is essential for the product's safety and efficacy. This application demonstrates a paradigm shift in Dextran's utility, where its physicochemical properties as a stable, biocompatible polymer are leveraged to deliver another therapeutic agent, arguably representing its most durable clinical contribution.

3.5. Analysis of Key Clinical Trials and Evidence Base

The clinical development and investigation of Dextran have spanned various therapeutic areas, with mixed outcomes that reflect its evolving role in medicine. A review of registered clinical trials provides insight into its areas of application and potential limitations.

• Brain Injury: Dextran was studied as part of a hypertonic resuscitation fluid for traumatic brain injury (TBI). A Phase 2/3 feasibility trial (NCT00878631) combining hypertonic saline and dextran was completed.[50] However, a separate, large Phase 3 trial (NCT00316004) investigating a similar combination for severe TBI was terminated.[51] The termination of this latter trial represents a significant setback for the use of Dextran in this critical care setting and suggests that its benefit may not have outweighed the risks or that it failed to show superiority over standard care.
• Iron Deficiency Anemia (IDA): A Phase 1/2 trial (NCT03279536) was completed to evaluate the use of Iron Dextran administered as a total dose infusion for treating IDA in pregnancy.[52] The completion of this trial underscores the continued clinical relevance and investigation of the Iron Dextran complex.
• Ophthalmology: Dextran was included as a component in ophthalmic solutions evaluated in two completed Phase 4 trials (NCT01732757, NCT01470118) for acute allergic conjunctivitis, confirming its established role as a vehicle and lubricant in eye drops.[53]
• Phenylketonuria (PKU): Dextran was listed as a component in a completed Phase 3 trial (NCT01889862) for PKU, which evaluated the drug Pegvaliase.[54] In this context, Dextran was not the primary therapeutic agent but likely served as a critical excipient in the formulation of Pegvaliase, possibly to modify its stability or pharmacokinetic profile.

This clinical trial landscape, summarized in Table 2, supports the observation of a shift in Dextran's primary application. While its role in critical care (e.g., TBI) has faced challenges, its utility as a carrier for iron and as a functional excipient in complex formulations remains an active area of clinical use and investigation.

Table 2: Summary of Key Clinical Trials Involving Dextran (DB09255)

Trial Identifier	Phase	Condition	Intervention (Dextran Role)	Status	Key Insight
NCT00878631	2 / 3	Brain Injury	Component of hypertonic resuscitation fluid (API)	Completed	Investigated for use in prehospital TBI treatment.50
NCT00316004	3	Traumatic Brain Injury (TBI)	Component of hypertonic resuscitation fluid (API)	Terminated	Termination suggests lack of efficacy or safety concerns, a setback for its use in critical care.51
NCT03279536	1 / 2	Iron Deficiency Anemia (IDA)	Carrier in Iron Dextran complex	Completed	Confirms ongoing clinical relevance and investigation of Iron Dextran for treating IDA.52
NCT01732757	4	Allergic Conjunctivitis	Lubricant/vehicle in ophthalmic solution (Excipient)	Completed	Supports established role as a key component in artificial tear formulations.53
NCT01889862	3	Phenylketonuria (PKU)	Component in Pegvaliase formulation (Excipient)	Completed	Demonstrates utility as a functional excipient in complex biologic drug formulations.54

Section 4: Advanced and Investigational Applications

Beyond its established clinical indications, Dextran's unique properties have made it a valuable tool in specialized medical procedures, diagnostic imaging, and as a foundational platform for advanced pharmaceutical technologies. These applications highlight a significant transition for Dextran, from a conventional drug to a versatile enabling technology in modern medicine and research.

4.1. Off-Label and Specialized Clinical Uses

Certain clinical applications of Dextran, while not part of its formal labeled indications, have become established in specific medical fields.

• Microsurgery: Dextran 40 is commonly used by microsurgeons as an off-label agent to enhance the patency of microanastomoses.[7] Its ability to improve microcirculatory flow, reduce blood viscosity, and inhibit platelet aggregation is thought to decrease the risk of vascular thrombosis in delicate procedures such as reconstructive plastic surgery, free flap transfers, and corneal grafts.[24] Despite this common use, it is noted that alternative antithrombotic strategies are often preferred, likely due to Dextran's safety profile.[24]
• Diagnostic Imaging: Dextran can be chelated with radionuclides, such as Technetium-99m, to create a radiopharmaceutical imaging agent.[5] When administered intravenously, this labeled Dextran is retained within the vascular compartment, allowing for clear imaging of the blood pool via techniques like scintigraphy or MRI. This application is used to detect and diagnose conditions such as pericardial effusions and ventricular aneurysms.[4] More recently, the inherent magnetic properties of the iron core in the Iron Dextran complex have been exploited for off-label use as an intravascular MRI contrast agent, enabling high-resolution imaging of small arterial and venous vessels in the brain.[55]
• Total Dose Infusion (TDI) of Iron Dextran: A significant off-label practice involves the administration of Iron Dextran via Total Dose Infusion (TDI). The FDA-approved labeling recommends a maximum daily dose of 100 mg (2 mL).[56] However, in TDI, the total calculated iron deficit for a patient is diluted in a saline bag and administered as a single, continuous infusion over several hours.[57] This approach is driven by pharmacoeconomics and patient convenience, as it consolidates what would be multiple clinic visits into a single treatment session, thereby reducing the cumulative risk of infusion-related events and saving resources.[57] This practice highlights a clinical judgment that the safety of modern low-molecular-weight Iron Dextran formulations is sufficient to justify this high-dose, off-label administration method for its logistical benefits.

4.2. Role as an Excipient in Advanced Drug Delivery Systems

Dextran's biocompatibility, biodegradability, and the presence of abundant hydroxyl groups for chemical modification make it an ideal polymer for pharmaceutical formulation and drug delivery.[12] It is used as a stabilizer, thickener, processing aid, and surface-finishing agent in both food and pharmaceutical industries.[5]

• Nanotechnology: Dextran is widely employed as a stabilizing coating for metallic nanoparticles, such as superparamagnetic iron oxide nanoparticles (SPIONs) and gold nanoparticles.[7] The dextran layer prevents nanoparticle aggregation, protects the metallic core from oxidation, and improves biocompatibility by masking the core from the immune system.[7] These dextran-coated nanoparticles are being extensively researched as platforms for targeted drug delivery, particularly in oncology, where they can be loaded with chemotherapeutics and directed to tumor tissues.[13]
• Microspheres, Micelles, and Hydrogels: Dextran can be formulated into various micro- and macro-scale structures for controlled drug release. Dextran microspheres can encapsulate drugs for targeted delivery to the colon.[60] Amphiphilic dextrans, modified with hydrophobic moieties, can self-assemble into micelles to encapsulate poorly water-soluble drugs.[13] Furthermore, dextran can be cross-linked to form hydrogels—highly absorbent polymer networks—that are biocompatible, biodegradable, and suitable for delivering therapeutics for bone diseases and cardiovascular conditions.[60]
• Prodrugs: The hydroxyl groups on the dextran backbone serve as attachment points for covalently linking drug molecules. This creates a dextran-drug conjugate, or prodrug, where the drug is inactive while attached to the polymer.[13] The bulky dextran matrix can protect the drug from premature enzymatic degradation. The drug is then released at the target site through the cleavage of the linker, which can be designed to be sensitive to specific physiological conditions, such as pH.[13]

4.3. Applications in Biomedical Research and Biotechnology

Dextran is a ubiquitous and indispensable tool in the life sciences laboratory.

• Separation and Chromatography: Cross-linked dextran beads are the basis for Sephadex, a widely used matrix for size-exclusion chromatography (gel filtration), a technique used to separate molecules based on size.[7] Additionally, dextran can be derivatized with charged groups (e.g., DEAE, CM) to create matrices for ion-exchange chromatography.[12]
• Cell Biology and Culture: In cell culture, dextran is sometimes added to media to enhance cell viability and productivity.[41] Colloidal dextran solutions are also used in density gradient centrifugation to isolate specific cell populations, such as lymphocytes and platelets, from whole blood.[9] Fluorescently-labeled dextran is used as a fluid-phase marker to visualize endocytosis and assess vascular permeability in research models.[7]
• Biophysical and Preclinical Research: Dextran is used in the osmotic stress technique to apply a controlled osmotic pressure to biological molecules, allowing researchers to study their hydration and conformational changes.[7] In animal models, dextran sodium sulfate is orally administered to induce colitis, providing a standard model for studying inflammatory bowel disease.[7]

The breadth of these advanced and investigational uses demonstrates that Dextran's value is increasingly found not in its own therapeutic effects, but in its role as a versatile and biocompatible platform. This shift from a simple medication to a foundational material for complex medical technologies represents a significant evolution in its lifecycle and points toward its future importance in pharmaceutics and biotechnology.

Section 5: Safety and Tolerability Profile

The clinical utility of Dextran is significantly constrained by a complex and potentially severe safety profile. The risks associated with its use are systemic, affecting the immunological, renal, hematological, and cardiovascular systems, and necessitate careful patient selection and intensive monitoring. A critical distinction must be made between the safety profile of Dextran used as a plasma expander (Dextran 40/70) and that of the Iron Dextran complex, which carries additional risks related to iron overload.

5.1. Adverse Drug Reactions and Toxicological Concerns

5.1.1. Hypersensitivity and Anaphylactoid Reactions: A Critical Risk

The most serious and well-documented adverse effect associated with Dextran administration is the risk of severe, life-threatening, and sometimes fatal anaphylactoid reactions.[27] These reactions are a major clinical concern and are highlighted with a boxed warning on Iron Dextran products.[63]

• Presentation and Onset: These reactions are often characterized by the sudden onset of respiratory distress (wheezing, bronchospasm), cardiovascular collapse, severe hypotension, and shock.[23] Other symptoms include urticaria, rash, itching, and angioedema (swelling of the face, tongue, or throat).[46] The reactions most frequently occur within the first few minutes of the infusion, often in patients with no prior exposure to parenteral Dextran.[31]
• Risk Factors: The underlying factors are not fully known, but patients with a history of asthma or multiple drug allergies may be at an increased risk.[45] Concomitant use of angiotensin-converting enzyme (ACE) inhibitors has also been suggested to increase the risk of reactions to Iron Dextran.[65]
• Risk Mitigation: Due to this risk, Dextran should only be administered in a setting where resuscitation equipment and personnel trained in the management of anaphylaxis are readily available.[58] For both Dextran 40/70 and Iron Dextran, administration of a small test dose is recommended prior to the first full therapeutic dose.[31] However, fatal reactions have occurred even after a tolerated test dose, underscoring the need for continuous vigilance during every infusion.[61] For infusions of Dextran 40 and Dextran 70, pre-administration of Dextran 1 (a monovalent hapten) is recommended. Dextran 1 is thought to bind to and neutralize pre-existing anti-dextran antibodies, thereby reducing the likelihood of a severe immune reaction upon exposure to the larger polymer.[22]

5.1.2. Renal, Hematologic, and Cardiovascular Effects

• Renal Toxicity: Dextran administration can lead to acute renal failure.[23] The mechanism is related to the high concentration of Dextran in the renal tubules, which increases urine viscosity and can lead to tubular obstruction.[24] Histologically, this can manifest as tubular vacuolization, a condition known as osmotic nephrosis.[31] The risk is particularly high in patients with pre-existing renal disease or in those who are dehydrated.[24] Careful monitoring of urine output is essential, and the drug should be discontinued if oliguria or anuria develops.[24]
• Hematologic Effects: Dextran interferes with hemostasis in a dose-dependent manner. Doses exceeding 1 liter of 10% Dextran 40 can cause a transient prolongation of bleeding time, depress platelet function, and reduce levels of coagulation factors V, IX, and von Willebrand factor.[4] This can result in an increased tendency for bleeding, which is a concern in postoperative patients or those with active hemorrhage.[4] Hematocrit should be monitored to avoid excessive hemodilution below 30%.[29]
• Cardiovascular Effects: As a potent plasma volume expander, Dextran can cause fluid overload, especially if infused too rapidly or in excessive volumes.[7] This can precipitate or exacerbate congestive heart failure and lead to pulmonary edema.[23] Patients with underlying cardiac disease are at particularly high risk, and monitoring of central venous pressure is recommended during rapid infusion.[29]

5.1.3. Other Adverse Effects and Iron Dextran Specifics

• Common and Delayed Reactions: More common, less severe adverse effects include nausea, vomiting, fever, flushing, dizziness, joint pain (arthralgia), and muscle pain (myalgia).[26] Delayed reactions, characterized by symptoms such as fever, backache, arthralgia, and malaise, can occur 24 to 48 hours after an infusion and typically resolve within 3 to 4 days.[46]
• Iron Dextran Specifics: In addition to the risks associated with the dextran component, Iron Dextran carries the risk of iron overload (iatrogenic hemosiderosis) if administered excessively.[49] This necessitates periodic monitoring of iron parameters such as serum ferritin and transferrin saturation.[62] Intramuscular injection can cause pain and long-lasting brown discoloration of the skin at the injection site.[44] There have also been reports linking intramuscular iron-carbohydrate complexes to sarcoma formation in animals.[61]

5.2. Contraindications and High-Risk Populations

Given its significant risk profile, Dextran is contraindicated in several patient populations.

• Absolute Contraindications:
• Known hypersensitivity to Dextran.[26]
• Marked cardiac decompensation or severe congestive heart failure.[26]
• Severe renal disease with oliguria or anuria.[28]
• Marked hemostatic defects of any type, including thrombocytopenia and hypofibrinogenemia.[26]
• For Iron Dextran: Anemias not associated with iron deficiency.[61]
• High-Risk Populations (Use with Caution):
• Patients with impaired renal or hepatic function.[26]
• Patients with active hemorrhage, as improved perfusion may increase blood loss.[68]
• Patients with rheumatoid arthritis, as Dextran may cause an acute exacerbation of joint pain and swelling.[62]
• Patients with a history of significant allergies or asthma.[46]

5.3. Clinically Significant Drug Interactions

The drug interaction profile of Dextran is complex and differs substantially between Dextran used for volume expansion and the Iron Dextran complex. The former is dominated by pharmacodynamic interactions affecting bleeding risk, while the latter is characterized by pharmacokinetic interactions affecting drug absorption.

5.3.1. Pharmacodynamic Interactions (Increased Bleeding Risk with Dextran 40/70)

The primary pharmacodynamic interaction for Dextran 40 and 70 is the additive risk of bleeding when co-administered with other drugs that affect hemostasis. This is a major and clinically significant class of interaction. The risk of bleeding and hemorrhage is increased when Dextran is combined with:

• Anticoagulants: Acenocoumarol, heparin, dabigatran, apixaban, rivaroxaban.[4]
• Antiplatelet Agents: Acetylsalicylic acid, abciximab, clopidogrel.[4]
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Aceclofenac, alclofenac, ibuprofen.[4]
• Thrombolytic Agents.[77]

5.3.2. Pharmacokinetic Interactions

• Some drugs may alter the pharmacokinetics of Dextran. For instance, drugs like acetaminophen and aldesleukin may decrease the excretion rate of Dextran, potentially leading to higher serum levels and increased risk of toxicity.[4] Conversely, diuretics like acetazolamide may increase Dextran's excretion rate, potentially reducing its efficacy.[4]

5.3.3. Iron Dextran Specific Interactions

The interaction profile of Iron Dextran is fundamentally different and is primarily related to chelation and absorption.

• Drugs that Decrease Iron Absorption: Agents that reduce gastric acidity (e.g., proton pump inhibitors like esomeprazole, H2-antagonists like famotidine) or that bind to iron (e.g., antacids containing aluminum hydroxide or calcium carbonate) can decrease the absorption and efficacy of concurrently administered oral iron, which is relevant for patients transitioning between therapies.[49]
• Iron Decreases Absorption of Other Drugs: Iron Dextran can decrease the absorption and serum concentration of several other drugs by forming non-absorbable complexes. This is particularly significant for:
• Quinolone and Tetracycline Antibiotics: Ciprofloxacin, levofloxacin, doxycycline, demeclocycline.[49]
• Other Medications: Levothyroxine, carbidopa, mycophenolate.[49]
• ACE Inhibitors: Concomitant use of ACE inhibitors (e.g., captopril, lisinopril) may increase the risk of hypersensitivity reactions to parenteral iron products.[49]

Table 3: Major Drug Interactions with Dextran Formulations and Clinical Management

Interacting Drug Class	Specific Examples	Dextran Formulation	Mechanism of Interaction	Clinical Consequence	Management Recommendation
Anticoagulants / Antiplatelet Agents	Heparin, Warfarin, Aspirin, Clopidogrel	Dextran 40 / 70	Additive pharmacodynamic effects on hemostasis	Increased risk of severe bleeding and hemorrhage 4	Avoid combination if possible. Monitor closely for signs of bleeding.
NSAIDs	Ibuprofen, Naproxen, Aceclofenac	Dextran 40 / 70	Additive antiplatelet effects and potential for GI bleeding	Increased risk of bleeding and hemorrhage 4	Use with extreme caution. Monitor coagulation parameters and signs of bleeding.
ACE Inhibitors	Captopril, Enalapril, Lisinopril	Iron Dextran	Unknown; may potentiate immune response	Increased risk of hypersensitivity/anaphylactoid reactions 49	Monitor patient closely during infusion. Be prepared to manage hypersensitivity.
Quinolone / Tetracycline Antibiotics	Ciprofloxacin, Doxycycline	Iron Dextran	Chelation of the antibiotic by iron, preventing absorption	Reduced serum concentration and potential therapeutic failure of the antibiotic 49	Administer oral antibiotics several hours before or after Iron Dextran infusion.
Acid-Reducing Agents (PPIs, H2-Blockers)	Esomeprazole, Famotidine	Iron Dextran	Decreased absorption of oral iron (relevant for transitioning therapy)	Reduced efficacy of oral iron supplements 49	Not a direct interaction with IV Iron Dextran, but relevant for overall iron management.

5.4. Interference with Laboratory Diagnostics

The presence of Dextran in the blood can interfere with several common laboratory tests, potentially leading to erroneous results and incorrect clinical decisions.

• Blood Typing and Cross-Matching: Dextran causes red blood cells to aggregate, a phenomenon known as rouleaux formation. This can interfere with standard cross-matching techniques.[29] To avoid this complication, it is strongly recommended that blood samples for typing and cross-matching be drawn before the Dextran infusion is initiated.[29]
• Biochemical Assays: Dextran can cause turbidity in serum samples, which may interfere with colorimetric and turbidimetric assays. This has been reported to cause falsely elevated values in serum bilirubin and total protein assays (using the biuret method).[26]
• Blood Glucose: Certain blood glucose measurement methods that use high concentrations of sulfuric or acetic acid for hydrolysis can break down the Dextran polymer into glucose, resulting in falsely elevated blood glucose readings.[31]
• Serum Iron: Following Iron Dextran administration, serum iron determinations may not be meaningful for up to 3 weeks.[61] Large doses can also impart a brown color to serum drawn 4 hours after administration.[56]

Section 6: Regulatory Landscape and Market Status

The regulatory history and current market status of Dextran provide a clear narrative of its evolving role in medicine. Analysis of its standing with major global health authorities like the U.S. FDA, the European Medicines Agency (EMA), and the World Health Organization (WHO) reveals a divergence: a contracting market presence as a plasma expander in developed nations, contrasted with its stable, long-standing approval as a critical component of Iron Dextran and its recognition as an essential medicine in global health contexts.

6.1. United States (FDA)

In the United States, Dextran's regulatory story is twofold.

• Approval History and Status: Iron Dextran has a long and established history of approval. The brand INFeD® (a low-molecular-weight iron dextran) was first approved by the FDA in 1974 for the treatment of documented iron-deficiency anemia in patients for whom oral iron therapy is unsatisfactory or impossible.[48] This indication remains current for adult and pediatric patients aged 4 months and older.[48] Other brands, such as Dexferrum®, are also approved for similar indications.[45] Dextran 40 and Dextran 70 have also been approved and used for decades as plasma volume expanders.[68] Separately, Dextran holds a Generally Recognized As Safe (GRAS) status, renewed in 2013, which pertains primarily to its use as a food additive and pharmaceutical excipient.[3]
• Regulatory Actions and Market Shifts: A significant regulatory event occurred in August 2012, when the FDA officially withdrew its approval of a New Drug Application (NDA 080-819) for DEXTRAN 70 (a 6% solution in 0.9% NaCl or 5% Dextrose) held by Hospira, Inc..[81] This action was taken at the request of the company, which stated that the product was no longer being marketed.[81] This withdrawal suggests a commercial shift away from Dextran 70 as a plasma expander, likely driven by the availability of alternative colloids and crystalloids with more favorable safety profiles. In contrast, low-molecular-weight iron dextran remains available and is the only formulation of its kind approved in the U.S..[48]
• Orphan Designation: Dextran sulfate has received an orphan designation from the FDA for use as an adjunct in the treatment of cystic fibrosis, though it has not been approved for this specific indication.[82]

6.2. Europe (EMA)

The European regulatory approach has focused on managing the known risks of parenteral iron products, including iron dextran.

• 2013 Safety Review: In June 2013, the EMA's Committee for Medicinal Products for Human Use (CHMP) completed a comprehensive review of all intravenous iron-containing medicines.[83] The review was initiated by the French medicines agency due to concerns about serious hypersensitivity reactions.[83] The CHMP concluded that the benefits of these medicines continue to outweigh their risks, but only if adequate measures are implemented to minimize the risk of allergic reactions. This led to a legally binding decision across the European Union to strengthen warnings and standardize risk management protocols, including recommendations for close patient monitoring during and after infusion and ensuring the immediate availability of resuscitation facilities.[83]
• Authorization Status: Unlike some drugs that receive centralized marketing authorization from the EMA, Dextran and its various formulations are authorized in the EU through national procedures in individual member states.[83] The EMA also provides guidance on the use of Dextran as an excipient in medicinal products, acknowledging its widespread use in pharmaceutical formulations.[85]

6.3. Australia (TGA)

Specific information on the approval status of Dextran products by the Australian Therapeutic Goods Administration (TGA) is not available in the provided documentation. However, the TGA's regulatory framework can be described.

• Regulatory Framework: The TGA regulates therapeutic goods through the Australian Register of Therapeutic Goods (ARTG).[86] Products are either "registered" (AUST R), which requires a full evaluation of quality, safety, and efficacy (typical for prescription medicines), or "listed" (AUST L), for lower-risk products like many complementary medicines.[86] Given its intended use and risk profile, any Dextran-containing prescription medicine would require AUST R registration. A search of a list of substances permitted in listed medicines does not show Dextran, reinforcing this conclusion.[88] The TGA also utilizes facilitated pathways and may rely on evaluation reports from trusted international regulators to expedite approvals.[89]

6.4. Global Standing: World Health Organization (WHO)

The WHO's perspective provides a crucial global health context for Dextran's utility.

• Essential Medicines List: Dextran 70, as a 6% injectable solution, is included on the WHO Model List of Essential Medicines.[8] It was first added in 1979 for the indication of hypovolemia.[36] Its inclusion on this list signifies that it is considered a critical medication for meeting the minimum needs of a basic healthcare system. This creates a notable dichotomy: while Dextran's use may be declining in high-resource settings with many alternatives, it remains essential in resource-limited environments where it may be one of the few available life-saving plasma volume expanders. In such contexts, its proven efficacy in treating hypovolemic shock is deemed to outweigh its significant safety risks, a benefit-risk calculation that differs from that in settings where safer alternatives are readily accessible.

This divergent regulatory narrative—a market contraction for Dextran as a plasma expander in the U.S., a focus on risk management for its iron complex in Europe, and its status as an essential medicine by the WHO—paints a complete picture of a legacy drug whose clinical value is now highly context-dependent.

Section 7: Concluding Analysis and Future Perspectives

7.1. Synthesis of the Benefit-Risk Profile

The comprehensive analysis of Dextran reveals a medication with a complex and dichotomous benefit-risk profile that has profoundly shaped its clinical trajectory. Its benefits are clear and well-established: as a plasma volume expander, it offers effective and rapid restoration of circulating volume in hypovolemic shock, and as an antithrombotic, it provides a unique mechanism for preventing venous thromboembolism. Furthermore, its role as a carrier in the Iron Dextran complex provides a life-saving therapeutic option for patients with severe iron-deficiency anemia who have exhausted oral treatment possibilities.

However, these benefits are weighed against a formidable array of risks. The potential for sudden, unpredictable, and fatal anaphylactoid reactions represents the most significant safety concern and mandates its administration in controlled settings with immediate access to resuscitation capabilities. Beyond this acute immunological risk, Dextran poses dose-dependent threats to multiple organ systems, including acute renal failure through osmotic nephrosis, clinically significant coagulopathy through interference with platelet and factor function, and cardiovascular decompensation from fluid overload. This systemic risk profile necessitates a high degree of clinical vigilance, including intensive monitoring of hemodynamic status, renal function, and hematological parameters.

This challenging safety profile is a primary driver for the observable shift in its clinical use. In many high-resource healthcare systems, safer alternatives such as crystalloid solutions and other colloids (e.g., albumin) have largely supplanted Dextran as a first-line plasma expander. The withdrawal of a Dextran 70 product from the U.S. market is a testament to this trend. In contrast, the benefit-risk profile for the low-molecular-weight Iron Dextran complex remains favorable, as it addresses a critical unmet need for patients intolerant to oral iron. For this population, the therapeutic benefit is substantial, and the risks, while serious, are considered manageable with appropriate precautions such as test dosing and careful monitoring. The inclusion of Dextran 70 on the WHO Essential Medicines List further highlights this context-dependent assessment, acknowledging that in resource-limited settings, its life-saving efficacy in shock outweighs its inherent risks.

7.2. Future Directions in Dextran Research and Clinical Use

The future of Dextran in medicine appears to be one of transformation rather than obsolescence. While its role as a standalone therapeutic agent for shock and VTE prophylaxis is likely to continue diminishing in favor of safer alternatives, its utility as a versatile biomaterial and platform technology is expanding. The evidence strongly suggests a pivot from Dextran as a drug to Dextran as a foundational technology in pharmaceutics and biotechnology.

Future research and development will likely focus on leveraging its advantageous properties—biocompatibility, biodegradability, high water solubility, and chemical functionality. Key areas of exploration include:

• Advanced Drug Delivery: The most promising future for Dextran lies in its application as a drug delivery vehicle. Research into Dextran-coated nanoparticles, hydrogels, micelles, and polymer-drug conjugates will continue to grow. These systems offer the potential for targeted delivery of therapeutics (e.g., chemotherapeutics, nucleic acids) to specific tissues, improving efficacy while minimizing systemic toxicity.
• Modification for Reduced Immunogenicity: A critical area for innovation will be the chemical modification of the Dextran polymer to reduce or eliminate its potential to cause hypersensitivity reactions. Creating less immunogenic versions of Dextran could revitalize its use and expand the safety of Dextran-based delivery systems.
• Diagnostic and Research Applications: Dextran's role as a diagnostic tool, both as a labeled imaging agent and as a component of contrast media, is likely to expand with advances in medical imaging technologies. In the laboratory, its established use in chromatography and cell biology will continue, and new derivatives will likely be developed for more specialized research applications.

In conclusion, Dextran stands as a mature pharmaceutical agent whose journey reflects the broader evolution of medicine. Its initial role as a simple but effective life-saving fluid is being eclipsed by its more sophisticated application as an enabling component in the next generation of targeted therapies, diagnostics, and biomedical technologies. The future of Dextran is not as a frontline drug, but as a quiet, indispensable workhorse of modern pharmaceutical science.

Works cited

1. Dextran | CAS 9004-54-0 | SCBT - Santa Cruz Biotechnology, accessed September 24, 2025, https://www.scbt.com/p/dextran-9004-54-0
2. CAS Number 9004-54-0 | Dextran - Spectrum Chemical, accessed September 24, 2025, https://www.spectrumchemical.com/cas/9004-54-0
3. Dextran at a Glance: Structure, Function & Biocompatibility, accessed September 24, 2025, https://dextran.com/dextran-insights/the-science-of-dextran-becomes-dextran/dextran-chemistry-properties/
4. Dextran: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 24, 2025, https://go.drugbank.com/drugs/DB09255
5. Dextran - PubChem, accessed September 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dextran
6. (PDF) Dextran: Sources, Structures, and Properties - ResearchGate, accessed September 24, 2025, https://www.researchgate.net/publication/352929357_Dextran_Sources_Structures_and_Properties
7. Dextran - Wikipedia, accessed September 24, 2025, https://en.wikipedia.org/wiki/Dextran
8. Dextran: Application, pharmacokinetics and toxicity - ChemicalBook, accessed September 24, 2025, https://www.chemicalbook.com/article/dextran-application-pharmacokinetics-and-toxicity.htm
9. Dextran - Sigma-Aldrich, accessed September 24, 2025, https://www.sigmaaldrich.com/US/en/technical-documents/protocol/protein-biology/protein-pulldown/dextran
10. Dextran | 9004-54-0 - ChemicalBook, accessed September 24, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8670298.htm
11. Dextran structure and degrees of branching, accessed September 24, 2025, https://dextran.com/dextran-chemistry/dextran-structure/
12. Dextran and Polysaccharides Overview - Sigma-Aldrich, accessed September 24, 2025, https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/protein-biology/protein-purification/dextran-and-related
13. What Are Dextrans? - CD Bioparticles Blog, accessed September 24, 2025, https://www.cd-bioparticles.net/blog/what-are-dextrans/
14. www.sigmaaldrich.com, accessed September 24, 2025, https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/protein-biology/protein-purification/dextran-and-related#:~:text=The%20name%20dextran%20was%20created,and%20a%20positive%20optical%20rotation.&text=Dextrans%20are%20polysaccharides%20with%20molecular,linked%20d%2Dglucopyranosyl%20repeating%20units.
15. Dextran | Platelet aggregation - TargetMol, accessed September 24, 2025, https://www.targetmol.com/compound/dextran
16. CAS RN 9004-54-0 - Fisher Scientific, accessed September 24, 2025, https://www.fishersci.com/us/en/browse/cas/9004-54-0
17. dextran.com, accessed September 24, 2025, https://dextran.com/dextran-chemistry/physical-properties-dextran/#:~:text=Dextrans%20come%20in%20a%20wide,maintain%20a%20favourable%20osmotic%20environment.
18. Physical properties of dextran molecules and fractions, accessed September 24, 2025, https://dextran.com/dextran-chemistry/physical-properties-dextran/
19. Dextran 40 (Mw.=ca. 40000) - TCI Chemicals, accessed September 24, 2025, https://www.tcichemicals.com/US/en/p/D1448
20. dextran 40 Clinical Pharmacology | Pfizer Medical - US, accessed September 24, 2025, https://www.pfizermedical.com/dextran/clinical-pharmacology
21. 10% LMD in 5% Dextrose Injection Rx only (Dextran 40 in Dextrose Injection, USP), accessed September 24, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=5407
22. 10% LMD in 5% Dextrose Injection Rx only (Dextran 40 in Dextrose Injection, USP) - DailyMed, accessed September 24, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3c273512-84e2-2cea-b201-12345a6bd1fe
23. Dextran (STORES PRODUCT) - CHEO ED Outreach, accessed September 24, 2025, https://outreach.cheo.on.ca/manual/1545
24. Dextran - StatPearls - NCBI Bookshelf, accessed September 24, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557631/
25. Pharmacokinetics of Dextran-70 in patients with cirrhosis and ascites undergoing therapeutic paracentesis - PubMed, accessed September 24, 2025, https://pubmed.ncbi.nlm.nih.gov/8895012/
26. Dextran - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose | Drug Index | Pediatric Oncall, accessed September 24, 2025, https://www.pediatriconcall.com/drugs/dextran/478
27. Pharmacology Of Dextran (Dextran 40) ; Pharmacokinetics, Mechanism of Action, Uses, Effects - YouTube, accessed September 24, 2025, https://www.youtube.com/watch?v=RQU4d2ugJiA
28. Dextran high molecular weight Uses, Side Effects & Warnings - Drugs.com, accessed September 24, 2025, https://www.drugs.com/mtm/dextran-high-molecular-weight.html
29. dextran 40 | Pfizer Medical - US, accessed September 24, 2025, https://www.pfizermedical.com/dextran
30. CAS RN | 9004-54-0 - Thermo Fisher Scientific, accessed September 24, 2025, https://www.thermofisher.com/search/cas/9004-54-0
31. dextran 40 Warnings and Precautions | Pfizer Medical - US, accessed September 24, 2025, https://www.pfizermedical.com/dextran/warnings
32. dextran 40 Dosage and Administration | Pfizer Medical - US, accessed September 24, 2025, https://www.pfizermedical.com/dextran/dosage-admin
33. Figure 1. Distribution and pharmacokinetics of dextran-coated AuNPs.... - ResearchGate, accessed September 24, 2025, https://www.researchgate.net/figure/Distribution-and-pharmacokinetics-of-dextran-coated-AuNPs-The-concentration-of-AuNPs-in_fig1_366322346
34. dextran 40 Indications and Usage | Pfizer Medical - US, accessed September 24, 2025, https://www.pfizermedical.com/dextran/indications-usage
35. Dextran 70 - PubChem, accessed September 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dextran-70
36. Dextran 70 - eEML - Electronic Essential Medicines List, accessed September 24, 2025, https://list.essentialmeds.org/medicines/472
37. dextran 70-hypromellose (PF) 0.1 %-0.3 % eye drops in a dropperette | Kaiser Permanente, accessed September 24, 2025, https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.dextran-70-hypromellose-pf-0-1-0-3-eye-drops-in-a-dropperette.559113
38. Dextran 70-Hypromellose Ophthalmic (Eye): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed September 24, 2025, https://www.webmd.com/drugs/2/drug-60553/dextran-70-hypromellose-ophthalmic-eye/details
39. WALGREENS ARTIFICIAL TEARS EYE DROPS- dextran 70 solution - FDA.report, accessed September 24, 2025, https://fda.report/DailyMed/1c0cf99a-8240-480f-8058-9e2243f95b5d
40. WALGREENS EYE DROPS ADVANCED RELIEF 15ML- dextran 70, polyethylene glycol 400, povidone, tetrahydrozoline hci solution/ drops - DailyMed, accessed September 24, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=949f5560-fba7-2da8-e053-2995a90a23c2
41. Pharmacosmos high quality dextrans for any application, accessed September 24, 2025, https://dextran.com/dextran-applications/
42. What is the mechanism of Iron Dextran? - Patsnap Synapse, accessed September 24, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-iron-dextran
43. Iron Dextran - StatPearls - NCBI Bookshelf, accessed September 24, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557747/
44. US5624668A - Iron dextran formulations - Google Patents, accessed September 24, 2025, https://patents.google.com/patent/US5624668A/en
45. Iron dextran (injection route) - Side effects & uses - Mayo Clinic, accessed September 24, 2025, https://www.mayoclinic.org/drugs-supplements/iron-dextran-injection-route/description/drg-20312466
46. Iron Dextran Injection: MedlinePlus Drug Information, accessed September 24, 2025, https://medlineplus.gov/druginfo/meds/a614033.html
47. Iron Dextran - PubMed, accessed September 24, 2025, https://pubmed.ncbi.nlm.nih.gov/32491679/
48. Why INFeD, accessed September 24, 2025, https://www.infed.com/why-infed
49. Iron Dextran: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 24, 2025, https://go.drugbank.com/drugs/DB00893
50. Dextran Completed Phase 2 / 3 Trials for Brain Injury Treatment | DrugBank Online, accessed September 24, 2025, https://go.drugbank.com/drugs/DB09255/clinical_trials?conditions=DBCOND0028243&phase=2%2C3&purpose=treatment&status=completed
51. Dextran Terminated Phase 3 Trials for Traumatic Brain Injury (TBI) Treatment - DrugBank, accessed September 24, 2025, https://go.drugbank.com/drugs/DB09255/clinical_trials?conditions=DBCOND0047292&phase=3&purpose=treatment&status=terminated
52. Dextran Completed Phase 1 / 2 Trials for Iron Deficiency Anemia (IDA) Treatment, accessed September 24, 2025, https://go.drugbank.com/drugs/DB09255/clinical_trials?conditions=DBCOND0047602&phase=1%2C2&purpose=treatment&status=completed
53. Dextran Completed Phase 4 Trials for Allergic Conjunctivitis (AC) Treatment - DrugBank, accessed September 24, 2025, https://go.drugbank.com/drugs/DB09255/clinical_trials?conditions=DBCOND0076634&phase=4&purpose=treatment&status=completed
54. Dextran Completed Phase 3 Trials for Phenylketonuria (PKU) Treatment | DrugBank Online, accessed September 24, 2025, https://go.drugbank.com/drugs/DB09255/clinical_trials?conditions=DBCOND0058086&phase=3&purpose=treatment&status=completed
55. Imaging arterial and venous vessels using Iron Dextran enhanced multi-echo 3D gradient echo MRI at 7T - PubMed, accessed September 24, 2025, https://pubmed.ncbi.nlm.nih.gov/39187441/
56. Dexferrum Label - accessdata.fda.gov, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/040024s022lbl.pdf
57. IV Iron Dextran Infusion Protocol | MedStar Health, accessed September 24, 2025, https://www.medstarhealth.org/news-and-publications/articles-and-research-reports/iv-iron-dextran-infusion-protocol
58. Iron Dextran Monograph for Professionals - Drugs.com, accessed September 24, 2025, https://www.drugs.com/monograph/iron-dextran.html
59. IV iron formulations and use in adults | Hematology, ASH Education Program, accessed September 24, 2025, https://ashpublications.org/hematology/article/2023/1/622/506478/IV-iron-formulations-and-use-in-adults
60. Dextran drug delivery systems - Wikipedia, accessed September 24, 2025, https://en.wikipedia.org/wiki/Dextran_drug_delivery_systems
61. INFeD® (IRON DEXTRAN INJECTION USP) Rx only Revised: September 2020 | FDA, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/017441s178lbl.pdf
62. INFeD® (iron dextran injection): Homepage, accessed September 24, 2025, https://www.infed.com/
63. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/017441s179lbl.pdf
64. Iron dextran (INFeD) - UPMC, accessed September 24, 2025, https://dam.upmc.com/-/media/cancercenter/for-patients/documents/chemo-pdfs/iron-dextran.pdf?rev=2c281797491941a18290f8964480cf86&hash=AF2C4EF5A3C3422913FC3167AA76F7E5
65. Iron Dextran Complex: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 24, 2025, https://www.rxlist.com/iron_dextran_complex/generic-drug.htm
66. Approved Label - accessdata.fda.gov, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017441s171lbl.pdf
67. iron dextran, accessed September 24, 2025, https://www.glowm.com/resources/glowm/cd/pages/drugs/ij025.html
68. Dextran 40 Monograph for Professionals - Drugs.com, accessed September 24, 2025, https://www.drugs.com/monograph/dextran-40.html
69. Dextran | Drug Lookup | Pediatric Care Online, accessed September 24, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5445/Dextran
70. Dextran - Uses, Dosage, Side Effects, Price, Composition | Practo, accessed September 24, 2025, https://www.practo.com/medicine-info/dextran-757-api
71. INFeD (Iron Dextran): Uses, Side Effects, Dosage & More - GoodRx, accessed September 24, 2025, https://www.goodrx.com/infed/what-is
72. Iron dextran Uses, Side Effects & Warnings - Drugs.com, accessed September 24, 2025, https://www.drugs.com/mtm/iron-dextran.html
73. dextran 40 Contraindications | Pfizer Medical - US, accessed September 24, 2025, https://www.pfizermedical.com/dextran/contradictions
74. Gentran 40 with 5% Dextrose Interactions - Drugs.com, accessed September 24, 2025, https://www.drugs.com/drug-interactions/dextran-low-molecular-weight,gentran-40-with-5-dextrose.html
75. Dextran, high molecular weight Interactions - Drugs.com, accessed September 24, 2025, https://www.drugs.com/drug-interactions/dextran-high-molecular-weight.html
76. go.drugbank.com, accessed September 24, 2025, https://go.drugbank.com/drugs/DB09255#:~:text=Dextran%20may%20increase%20the%20anticoagulant%20activities%20of%20Abciximab.&text=The%20risk%20or%20severity%20of,Aceclofenac%20is%20combined%20with%20Dextran.&text=Acemetacin-,The%20risk%20or%20severity%20of%20bleeding%20and%20hemorrhage%20can%20be,Dextran%20is%20combined%20with%20Acemetacin.
77. Dextran 40 in 0.9% Sodium Chloride and revakinagene taroretcel Interactions - Drugs.com, accessed September 24, 2025, https://www.drugs.com/drug-interactions/dextran-40-in-0-9-sodium-chloride-with-revakinagene-taroretcel-841-5779-4682-0.html
78. Iron dextran Interactions Checker - Drugs.com, accessed September 24, 2025, https://www.drugs.com/drug-interactions/iron-dextran.html
79. Dextran 70 6% in 5% Dextrose high molecular weight Uses, Side Effects & Warnings, accessed September 24, 2025, https://www.drugs.com/mtm/dextran-70-6-in-5-dextrose-high-molecular-weight.html
80. Dextran safety, accessed September 24, 2025, https://dextran.com/dextran-chemistry/dextran-safety/
81. Hospira, Inc.; Withdrawal of Approval of a New Drug Application for DEXTRAN 70, accessed September 24, 2025, https://www.federalregister.gov/documents/2012/08/20/2012-20280/hospira-inc-withdrawal-of-approval-of-a-new-drug-application-for-dextran-70
82. Search Orphan Drug Designations and Approvals - FDA, accessed September 24, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=050690
83. Intravenous iron-containing medicinal products - referral | European Medicines Agency (EMA), accessed September 24, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/intravenous-iron-containing-medicinal-products
84. iron dextran: List of nationally authorised medicinal products - PSUSA/00010696/202101, accessed September 24, 2025, https://www.ema.europa.eu/en/documents/psusa/iron-dextran-list-nationally-authorised-medicinal-products-psusa00010696202101_en.pdf
85. Information for the package leaflet regarding dextrans used as excipients in medicinal products for human use, accessed September 24, 2025, https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-regarding-dextrans-used-excipients-medicinal-products-human-use_en.pdf
86. What does TGA approval of medicines mean? - Australian Prescriber, accessed September 24, 2025, https://australianprescriber.tg.org.au/articles/what-does-tga-approval-of-medicines-mean.html
87. Australian Register of Therapeutic Goods (ARTG), accessed September 24, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
88. Substances that may be used in Listed medicines in Australia - Therapeutic Goods Administration (TGA), accessed September 24, 2025, https://www.tga.gov.au/sites/default/files/cm-listed-substances_0.pdf
89. Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia - PMC, accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9589776/